Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Analysts following Egetis

ABG Sundal Collier: Alexander Krämer

Bryan, Garnier & Co: Oscar Haffen Lamm

Carnegie: Arvid Necander & Erik Hultgård

DNB: Patrik Ling

Handelsbanken: Suzanna Queckbörner & Mattias Häggblom

Pareto Securities: Chien-Hsun Lee

Redeye: Fredrik Thor

 

 

 

 

 

Calendar and upcoming reports

April 2, 2025
Van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 30, 2025
Interim Report Q1 2025 (7:00am CEST)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]